At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 183 enrolled
Drug / intervention
Oral Lenacapavir +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
In Brief
A Phase 2 clinical trial evaluating Oral Lenacapavir, F/TAF, and 4 other interventions for HIV-1-infection. Completed, enrolled 183 participants across 53 sites in 3 countries.
Detailed Summary
The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1-infection
CountriesDominican Republic, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartNov 2019
Primary CompletionOct 2021
Study CompletionSep 2023
TodayJul 2026
First PostedOct 29, 2019
Enrollment StartNov 22, 2019
Primary CompletionOct 5, 2021
Study CompletionSep 19, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.7 years ago
Interventions
Oral Lenacapavirdrug
Tablets administered without regard to food
F/TAFdrug
Tablets administered without regard to food
Subcutaneous Lenacapavirdrug
Administered in the abdomen via subcutaneous injections
TAFdrug
Tablets administered without regard to food
BICdrug
Tablets administered without regard to food
B/F/TAFdrug
Tablets administered without regard to food